Trinity Biotech (TRIB) Projected to Post Quarterly Earnings on Wednesday

Trinity Biotech (NASDAQ:TRIB) is expected to announce its Q4 2025 resultson Wednesday, April 8th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $15.00 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, April 13, 2026 at 9:30 AM ET.

Trinity Biotech (NASDAQ:TRIB) last released its earnings results on Friday, January 2nd. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($1.48) by $1.16. The firm had revenue of $9.20 million during the quarter, compared to analysts’ expectations of $10.50 million. On average, analysts expect Trinity Biotech to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Trinity Biotech Stock Performance

Shares of NASDAQ:TRIB opened at $0.60 on Monday. The firm has a 50 day simple moving average of $0.73 and a 200 day simple moving average of $0.87. Trinity Biotech has a 52 week low of $0.48 and a 52 week high of $3.44. The company has a market cap of $2.16 million and a PE ratio of -0.06.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Trinity Biotech in a research note on Wednesday, March 25th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Trinity Biotech

An institutional investor recently bought a new position in Trinity Biotech stock. Perceptive Advisors LLC purchased a new position in Trinity Biotech PLC (NASDAQ:TRIB) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,790,000 shares of the company’s stock, valued at approximately $1,164,000. Perceptive Advisors LLC owned approximately 9.92% of Trinity Biotech at the end of the most recent reporting period. 78.97% of the stock is currently owned by institutional investors and hedge funds.

About Trinity Biotech

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.